Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis

被引:108
作者
Han, YM
Kozel, TR
Zhang, MX
MacGill, RS
Carroll, MC
Cutler, JE
机构
[1] Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA
[2] Univ Nevada, Sch Med, Dept Microbiol, Reno, NV 89557 USA
[3] Univ Nevada, Cell & Mol Biol Program, Reno, NV 89557 USA
[4] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.4049/jimmunol.167.3.1550
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The incidence of life-threatening, hematogenously disseminated candidiasis, which is predominantly caused by Candida albicans, parallels the use of modern medical procedures that adversely affect the immune system. Limited antifungal drug choices and emergence of drug-resistant C albicans strains indicate the need for novel prevention and therapeutic strategies. We are developing vaccines and Abs that enhance resistance against experimental candidiasis. However, the prevalence of serum anti-Candida Abs in candidiasis patients has led to the misconception that Abs are not protective. To explain the apparent discrepancy between such clinical observations and our work, we compared functional activities of C. albicans-specific protective and nonprotective mAbs. Both kinds of Abs are agglutinins that fix complement and are specific for cell surface mannan, but the protective Abs recognize beta -mannan, and the nonprotective Ab is specific for a-mannan. By several indirect and direct measures, the protective mAbs more efficiently bind complement factor C3 to the yeast cell than do nonprotective Ab. We hypothesize that the C3 deposition causes preferential association of blood-borne fungi with host phagocytic cells that are capable of killing the fungus. We conclude from these results that the protective potential of Abs is dependent on epitope specificity, serum titer, and ability to rapidly and efficiently fix complement to the fungal surface. The mechanism of protection appears to be associated with enhanced phagocytosis and killing of the fungus.
引用
收藏
页码:1550 / 1557
页数:8
相关论文
共 58 条
[1]  
ANAISSIE E, 1989, NOSOCOMIAL INFECT NE, P867
[2]   EVIDENCE FOR MACROPHAGE-MEDIATED PROTECTION AGAINST LETHAL CANDIDA-ALBICANS INFECTION [J].
BISTONI, F ;
VECCHIARELLI, A ;
CENCI, E ;
PUCCETTI, P ;
MARCONI, P ;
CASSONE, A .
INFECTION AND IMMUNITY, 1986, 51 (02) :668-674
[3]   THE EMERGENCE OF FUNGI AS MAJOR HOSPITAL PATHOGENS [J].
BODEY, GP .
JOURNAL OF HOSPITAL INFECTION, 1988, 11 :411-426
[4]   A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity [J].
CaesarTonThat, TC ;
Cutler, JE .
INFECTION AND IMMUNITY, 1997, 65 (12) :5354-5357
[5]   Antibodies, killer toxins and antifungal immunoprotection: A lesson from nature [J].
Cassone, A ;
Conti, S ;
DeBernardis, F ;
Polonelli, L .
IMMUNOLOGY TODAY, 1997, 18 (04) :164-169
[6]   RATS CLEARING A VAGINAL INFECTION BY CANDIDA-ALBICANS ACQUIRE SPECIFIC, ANTIBODY-MEDIATED RESISTANCE TO VAGINAL REINFECTION [J].
CASSONE, A ;
BOCCANERA, M ;
ADRIANI, D ;
SANTONI, G ;
DEBERNARDIS, F .
INFECTION AND IMMUNITY, 1995, 63 (07) :2619-2624
[7]   MACROPHAGE COLONY-STIMULATING FACTOR IN MURINE CANDIDIASIS - SERUM AND TISSUE-LEVELS DURING INFECTION AND PROTECTIVE EFFECT OF EXOGENOUS ADMINISTRATION [J].
CENCI, E ;
BARTOCCI, A ;
PUCCETTI, P ;
MOCCI, S ;
STANLEY, ER ;
BISTONI, F .
INFECTION AND IMMUNITY, 1991, 59 (03) :868-872
[8]   Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats [J].
DeBernardis, F ;
Boccanera, M ;
Adriani, D ;
Spreghini, E ;
Santoni, G ;
Cassone, A .
INFECTION AND IMMUNITY, 1997, 65 (08) :3399-3405
[9]   SHOULD ALL PATIENTS WITH CANDIDEMIA BE TREATED WITH ANTIFUNGAL AGENTS [J].
EDWARDS, JE .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (03) :422-423
[10]   INVASIVE CANDIDA INFECTIONS - EVOLUTION OF A FUNGAL PATHOGEN [J].
EDWARDS, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (15) :1060-1062